Michel Azizi
Inserm · 676 works · 37,571 citations · h-index 76
Top works
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
- 2018 ESC/ESH Guidelines for the management of arterial hypertension
- 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
- Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial
- 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
- Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial
- Additive Effects of Combined Angiotensin-Converting Enzyme Inhibition and Angiotensin II Antagonism on Blood Pressure and Renin Release in Sodium-Depleted Normotensives
- First International Consensus on the diagnosis and management of fibromuscular dysplasia
- [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)].
- Restenosis after a first percutaneous transluminal renal angioplasty.
- Effects of chronic inhibition of converting enzyme on mechanical and structural properties of arteries in rat renovascular hypertension.
- Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.
- Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial
- Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19
- Home Blood-Pressure Monitoring in Patients Receiving Sunitinib
- European consensus on the diagnosis and management of fibromuscular dysplasia
- Renin inhibition with aliskiren: where are we now, and where are we going?
- Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II–Renin Feedback Interruption
- Combined Blockade of the Renin-Angiotensin System With Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Antagonists